MetaVia (NASDAQ:MTVA) Trading 8.8% Higher – Still a Buy?

MetaVia Inc. (NASDAQ:MTVA)’s stock price was up 8.8% on Friday . The company traded as high as $9.68 and last traded at $9.31. Approximately 80,665 shares were traded during trading, a decline of 67% from the average daily volume of 241,664 shares. The stock had previously closed at $8.56.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on MTVA shares. HC Wainwright initiated coverage on shares of MetaVia in a research note on Thursday, September 4th. They set a “buy” rating and a $132.00 price objective for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of MetaVia in a report on Wednesday, October 8th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $82.50.

MetaVia Price Performance

The firm’s 50-day moving average price is $9.62 and its 200-day moving average price is $8.59. The company has a market cap of $20.48 million, a price-to-earnings ratio of -1.11 and a beta of 0.29.

MetaVia (NASDAQ:MTVA) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($1.54) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.86) by $1.32. On average, sell-side analysts anticipate that MetaVia Inc. will post -3.9 earnings per share for the current year.

Institutional Investors Weigh In On MetaVia

An institutional investor recently bought a new position in MetaVia stock. Virtu Financial LLC purchased a new position in shares of MetaVia Inc. (NASDAQ:MTVA) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned approximately 0.14% of MetaVia as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 1.37% of the company’s stock.

MetaVia Company Profile

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.